
Naveen Pemmaraju, MD, discusses adverse effects associated with JAK inhibitors in the treatment of myelofibrosis, and the Oncology Brothers recap the entire discussion.

Your AI-Trained Oncology Knowledge Connection!


Naveen Pemmaraju, MD, discusses adverse effects associated with JAK inhibitors in the treatment of myelofibrosis, and the Oncology Brothers recap the entire discussion.

An expert on myelofibrosis discusses anemia and splenomegaly management practices for patients with myelofibrosis.

Naveen Pemmaraju, MD, gives a comprehensive overview of JAK inhibitors available for the treatment of patients with myelofibrosis.

A hematology specialist provides clinical insights on supportive care practices for patients with myelofibrosis.

Naveen Pemmaraju, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss diagnostic practices and prognostic factors for patients with myelofibrosis.

A recent clinical quandary focused on the diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm in a resource-limited setting.

Published: May 20th 2024 | Updated:

Published: May 20th 2024 | Updated:

Published: May 20th 2024 | Updated:

Published: March 6th 2024 | Updated:

Published: May 20th 2024 | Updated:

Published: May 20th 2024 | Updated: